The aluminium-[18F]fluoride revolution: simple radiochemistry with a big impact for radiolabelled biomolecules

The aluminium-[F-18]fluoride ([F-18]AlF) radiolabelling method combines the favourable decay characteristics of fluorine-18 with the convenience and familiarity of metal-based radiochemistry and has been used to parallel gallium-68 radiopharmaceutical developments. As such, the [F-18]AlF method is popular and widely implemented in the development of radiopharmaceuticals for the clinic. In this review, we capture the current status of [F-18]AlF-based technology and reflect upon its impact on nuclear medicine, as well as offering our perspective on what the future holds for this unique radiolabelling method.

Automated summary

The [F-18]AlF radiolabelling method, which combines the favorable decay characteristics of fluorine-18 with the convenience of metal-based radiochemistry, has been widely implemented in the development of radiopharmaceuticals for the clinic. This review captures the current status of [F-18]AlF-based technology and reflects on its impact on nuclear medicine, providing insights into the future prospects of this unique radiolabelling method.